RxDoctor Payments Data

Georg Couturier, MD

Cardiovascular Disease · The Villages, FLNPI 1710952486

Payments from drug & device makers

$23,131in general payments, 2019–2025

Across 565 payments — averaging $40.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$9K
  • Medtronic$3K
  • Abbott$2K
  • Boston Scientific$2K
  • Johnson & Johnson$869
  • Boehringer Ingelheim$832
  • plus $6K from 36 others

What the payments were for

  • Travel & lodging$11,59850%
  • Food & beverage$11,33049%
  • Education$2031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,131 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$3,037,157
Medicare patients
3,443
Services billed
25,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,076$1,463,145
EntrestoSacubitril/Valsartan279$396,322
XareltoRivaroxaban184$234,557
Repatha SureclickEvolocumab155$180,589
JardianceEmpagliflozin135$166,890
MultaqDronedarone Hcl51$82,889
FarxigaDapagliflozin Propanediol82$74,017
WegovySemaglutide43$60,961
Praluent PenAlirocumab40$49,404
OzempicSemaglutide38$38,775
BrilintaTicagrelor37$35,031
Dofetilide80$26,115
Repatha SyringeEvolocumab19$25,084
Metoprolol Succinate1,477$23,563
Ranolazine ErRanolazine125$14,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$550$1,463,1451,076 claims
NovartisEntresto$315$396,322279 claims
Johnson & JohnsonXarelto$869$234,557184 claims
Boehringer IngelheimJardiance$832$166,890135 claims
AstraZenecaFarxiga, Brilinta$413$109,049119 claims
Novo NordiskWegovy, Ozempic$145$99,73681 claims
Sanofi-aventis U.S. LLCMultaq$351$82,88951 claims
MerckVerquvo$520$10,54311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →